Astrazeneca (AZN) Capital Expenditures (2018 - 2026)

Astrazeneca has reported Capital Expenditures over the past 16 years, most recently at -$547.0 million for Q1 2026.

For Q1 2026, Capital Expenditures fell 27.51% year-over-year to -$547.0 million; the TTM value through Mar 2026 reached $2.7 billion, up 40.79%, while the annual FY2025 figure was $2.8 billion, 46.05% up from the prior year.
Capital Expenditures for Q1 2026 was -$547.0 million at Astrazeneca, down from $4.6 billion in the prior quarter.
Over five years, Capital Expenditures peaked at $4.6 billion in Q4 2025 and troughed at -$686.0 million in Q3 2025.
A 5-year average of $246.0 million and a median of -$382.0 million in 2024 define the central range for Capital Expenditures.
On a YoY basis, Capital Expenditures climbed as much as 45.99% in 2025 and fell as far as 72.51% in 2025.
Year by year, Capital Expenditures stood at -$253.0 million in 2022, then fell by 6.72% to -$270.0 million in 2023, then skyrocketed by 1262.96% to $3.1 billion in 2024, then skyrocketed by 45.99% to $4.6 billion in 2025, then plummeted by 111.93% to -$547.0 million in 2026.
Business Quant data shows Capital Expenditures for AZN at -$547.0 million in Q1 2026, $4.6 billion in Q4 2025, and -$686.0 million in Q3 2025.

Peer Comparison